The study published by Bastiaan M Privé and colleagues in The Lancet Oncology represents, to our knowledge, the first randomised phase 2 trial evaluating lutetium-177–PSMA-617 (177Lu-PSMA-617) in ...

Where previous research showed that PSMA therapy for prostate cancer can prolong the lives of patients who have exhausted all ...

Low testosterone may raise the risk of aggressive prostate cancer progression in men under monitoring, a study finds.

ORIC Pharmaceuticals (ORIC) lost ~22% in extended trading after the company reported data from a Phase 1b trial for its prostate cancer therapy rinzimetostat (ORIC-944) developed in combination with ...

Read more about how low testosterone levels are linked to ‘extreme’ disease progression in patients with prostate cancer ...

(HealthDay News) — Low testosterone levels may increase the risk of higher-grade “extreme” progression of prostate cancer among men enrolled in active surveillance (AS), according to a study published ...

Prostate cancer begins in the prostate, a small gland located just below the bladder, present only in people assigned male at birth (AMAB). This gland is in charge of producing seminal fluid, and it ...

The statistics are sobering and undeniable — African American men develop prostate cancer at twice the rate of white men and are more likely to die from the disease. This reality makes understanding ...

USA: A retrospective cohort study has found that low testosterone levels in patients with prostate cancer undergoing active ...

Researchers at Texas A&M Health have identified a molecular mechanism that increases cholesterol levels inside prostate ...

What did the study reveal about testosterone levels and cancer progression? Researchers found that prostate cancer patients with low baseline testosterone levels (300 ng/dl and lower) had a ...